Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.

V ChungF J KosN HardwickY YuanJ ChaoD LiJ WaismanM LiK ZurcherP FrankelDon J Diamond

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)

We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
advanced non small cell lung cancer
peritoneal dialysis
prognostic factors
tyrosine kinase